ErgoMed, Inc.

60 articles about ErgoMed, Inc.

• Ergomed strongly positioned for future growth in new partnership with Permira

  11/14/2023

  Ergomed plc and Permira Advisers LLP, are pleased to announce the completion of the acquisition of Ergomed by funds advised by Permira for £703.1 million.

• Ergomed Rare Disease Innovation Center to Leverage Medidata Patient Cloud, Intelligent Trials Technologies, and Synthetic Control Arm to Advance New Treatments

  5/5/2022

  Medidata , a Dassault Systèmes company, announced that Ergomed’s Rare Disease Innovation Center TM will leverage Medidata’s Patient Cloud, Intelligent Trials technologies, and Synthetic Control Arm Ⓡ to help sponsors reduce clinical trial timelines, optimize patient experiences, and bring effective rare disease therapies to market more quickly.

• Ergomed 2019 Trading Update

  1/29/2020

  Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces a trading update for the year ended 31 December 2019.

• Lewis Cameron, Former Head of Global Clinical Development at Covance, Appointed as Chief Operating Officer

  12/2/2019

  Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board, effective from January 20th, 2020.

• Ergomed plc: Interim results for the six months ended 30 June 2019

  9/25/2019

  Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.

• Ergomed plc: Board Change

  9/25/2019

  Ergomed plc,, a company focused on providing specialised services to the global pharmaceutical industry, announces that Peter George will step down from the Board with immediate effect to focus on his other business activities, in particular Benchmark Holdings plc where he was recently appointed Executive Chairman.

• Ergomed plc: Notice of Interim Results

  8/29/2019

  Ergomed plc will announce its interim results for the six months ending 30 June 2019 on 25September 2019.

• Ergomed H1 2019 Trading Update

  7/22/2019

  Revenue and EBITDA for full year 2019 expected to be ahead of market expectations

• Ergomed Board Appointments

  7/22/2019

  Appointments of Rolf Soderstrom and Dr Jim Esinhart as Non-Executive Directors

• Board Appointment: Dr Jim Esinhart, Former CEO of Chiltern International, Proposed Appointment as Non-Executive Director

  7/10/2019

  Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce its intention to appoint Dr Jim Esinhart as a Non-Executive Director of the Company.

• Ergomed Strengthens Executive Team with Appointment of Richard Barfield, Formerly of Chiltern International, as Chief Financial Officer

  6/4/2019

  Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Richard Barfield FCA as Chief Financial Officer, effective immediately.

• Ergomed on track to exceed 2019 market expectations following a strong start to the year

  5/16/2019

  Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces an update on trading for 2019

• Ergomed’s PrimeVigilance awarded 2019 Queen’s Award for Enterprise

  4/23/2019

  Awarded for year-on-year outstanding international trade performance Second Queen’s Award for Enterprise following previous award in 2014 in recognition of substantial growth and commercial success

• Ergomed plc: Unaudited Preliminary Results for the year ended 31 December 2018

  4/10/2019

  Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces its unaudited Preliminary Results for the year ended 31 December 2018.

• Ergomed plc: Roy Ovel appointed as Chief Commercial Officer

  4/2/2019

  Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.

• Ergomed plc: Notice of Preliminary Results

  4/2/2019

  Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its Preliminary Results for the full year ending 31 December 2018 on 10 April 2019.

• Ergomed plc: Proposed Board and Management Changes

  2/13/2019

  Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.

• Ergomed 2018 Trading Update

  1/31/2019

  Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, today provides a trading update for the year ended 31 December 2018.

• Ergomed Plc: Board and Management Changes

  1/23/2019

  Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, announces Board and management changes.

• Michael Spiteri appointed Non-Executive Director to help drive digitization strategy

  10/2/2018

  Ergomed plc today announces two Board changes with immediate effect.